Lv63
2078 积分 2021-04-23 加入
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
25天前
已完结
A daily clinical practice decision-making overview for the present metastatic renal cell carcinoma (mRCC) management landscape
1个月前
已关闭
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
2个月前
已完结
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
2个月前
已完结
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
4个月前
已完结
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
4个月前
已完结
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
5个月前
已完结
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer
7个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
8个月前
已完结
皖公网安备34019202002308
